Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odalasvir - Achillion Pharmaceuticals

Next Previous
Drug Profile

Odalasvir - Achillion Pharmaceuticals

Alternative Names: ACH-0143102; ACH-3102; JNJ-64289901; ODV

Latest Information Update: 29 Jul 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Achillion Pharmaceuticals
  • Developer Achillion Pharmaceuticals; Alios BioPharma
  • Class Antivirals; Benzimidazoles; Indoles; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
  • 24 Feb 2021 Discontinued - Phase-I for Hepatitis C (Combination therapy, In volunteers) in France (PO) (Alexion Pharmaceuticals pipeline, February 2021)
  • 24 Feb 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy) in Moldova, Mauritius, United Kingdom, Japan (PO) (Alexion Pharmaceuticals pipeline, February 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top